Soleno Therapeutics (SLNO) Fundamental Analysis: Revenue, Earnings & Valuation

0.64 / 10

Underperform

Fundamentally, SLNO is rated Underperform with a 0.6/10 score. Revenue‑MV and Cash‑UP are modest positives, while Profit‑MV, Asset‑MV and profit margins are poor. Overall quality is low, urging prudence.

Analysis Checks(2/10)

Revenue-MV

Value-1.08

Score3/3

Weight-12.27%

1M Return3.85%

Net cash flow from operating activities / Operating revenue (%)

Value24.58

Score0/3

Weight20.81%

1M Return-9.58%

Profit-MV

Value-0.86

Score1/3

Weight7.38%

1M Return-2.85%

Net income-Revenue

Value1.11

Score1/3

Weight6.61%

1M Return-2.58%

Net profit margin (%)

Value10.97

Score0/3

Weight20.36%

1M Return-9.31%

Cash-UP

Value-0.15

Score3/3

Weight-7.76%

1M Return2.45%

Net cash flow from operating activities / Total liabilities (%)

Value0.41

Score0/3

Weight14.89%

1M Return-6.78%

EBIT / Total operating revenue (%)

Value4.94

Score0/3

Weight19.93%

1M Return-9.03%

Asset-MV

Value-0.55

Score0/3

Weight9.69%

1M Return-3.70%

Net profit / Total operating revenue (%)

Value10.97

Score0/3

Weight20.36%

1M Return-9.31%

Is SLNO fundamentally strong?

SLNO scores 0.64/10 on fundamentals and holds a Premium valuation at present. Backed by its 5.89% ROE, 0.00% net margin, 75.77 P/E ratio, 3.45 P/B ratio, and 109.13% earnings growth, these metrics solidify its Underperform investment rating.